Idorsia
Katie Cheadle-Hunt is an experienced professional in drug regulatory affairs, currently serving as an Editorial Group Leader at Idorsia Pharmaceuticals Ltd since June 2017. In this role, Cheadle-Hunt leads a small team focused on the copy-editing and quality control of regulatory documents and journal publications, emphasizing collaboration across functions. Previously, Cheadle-Hunt was a Documentation Specialist at Actelion, handling proof-reading, copy-editing, and document version tracking. Early career experiences include teaching English as a foreign language at Castle's English Institute and academia Sprach- und Lernzentrum, as well as working as a Healthcare Assistant for 2gether NHS Trust. Cheadle-Hunt holds a Bachelor of Science in Psychology from the University of St Andrews and a CELTA qualification in Teaching English as a Second or Foreign Language.
This person is not in any teams
This person is not in any offices
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.